Cardiovascular Adverse Events Associated With Bispecific T-Cell Engager Therapy

Key Points

• The aim is to explore the cardiovascular risks linked to T-cell engager therapy in cancer treatment.
• Analysis of existing literature on T-cell engager therapy and cardiovascular outcomes.
• Review of known adverse events related to immunotherapies.
• Comparison of cardiovascular risks among various cancer therapies.
• Increased cardiovascular risks were noted in patients receiving T-cell engager therapy.
• Evidence of cardiovascular complications from T-cell engager therapies is limited but concerning.

Structured PICO

Abstract